Amino rūgšties priemaišos, naudojamos sintezuoti baltymą
Produkto detalė
| NO | Produktai | CAS Nr | Pagrindinis kokybės rodiklis | |||
| Grynumas | Maks. priemaiša | Bendras tirpiklio likutis | Drėgmė | |||
| 1 | FMOC-β-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-A ALA-D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 4 | Fmoc-arg (pbf) -rg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 5 | FMOC-β-ALA-ARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 6 | Fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 9 | FMOC-β-Ala-homoarg (PBF) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 12 | Fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 13 | FMOC-β-ALA-ASB (OTBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 16 | Fmoc-cys (acm) -cys (acm) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 22 | FMOC-β-ALA-Gly-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 23 | Fmoc-his (trt) -his (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 24 | Fmoc-β-his (TRT) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 26 | FMOC-β-Ala-Ile-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 28 | FMOC-β-a-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 30 | Fmoc-β-d-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 31 | FMOC-Lys (Boc) -Lys (Boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 32 | FMOC-β-ALAS (BOC) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-Lys (alloc) -Lys (Alloc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 34 | FMOC-β-Ala-Lys (alloc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-met-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 36 | FMOC-β-ALA-MET-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 37 | Fmoc-orn (boc) -orn (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 38 | FMOC-β-ALA-ONR (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 39 | FMOC-PHE-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 40 | FMOC-β-ALA-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 42 | FMOC-β-ALA-D-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 44 | FMOC-β-A-PRO-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 46 | FMOC-β-ALA-SER (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 48 | FMOC-β-ALA-SER (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 50 | FMOC-β-ALA-TR (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 51 | Fmoc-trp (boc) -trp (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 53 | Fmoc-d-trp (boc) -d-trp (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 56 | FMOC-β-ALA-Tyr (TBU) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 60 | FMOC-β-ALA-Tyr (Me) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 61 | Fmoc-val-val-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-ALA-Val-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-dab-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 66 | FMOC- (3- (2-naftil) -d-ALA) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-ALA-3- (2-naftil) -D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-piridinil) -d-ALA) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-ALA-3- (3-piridinil) -D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 70 | Fmoc- (4-chloro-d-phe) 2-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 71 | FMOC-β-A-4-chloro-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 73 | FMOC-β-A ALA-D-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 74 | FMOC-APH (L-HOR) -APH (L-HOR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 75 | FMOC-β-APH (L-HOR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 76 | FMOC-Lys (IPR, BOC) -Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 78 | FMOC-β-AAAEA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 80 | FMOC-β-A-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 82 | H-arg (PBF) -oh | 200115-86-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 86 | H-homoarg (PBF) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 88 | HD-homoarg (PBF) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (OTBU) -OH | 3057-74-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 94 | H-CYS (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 95 | H-CYS (ACM) -OH.HCl | 28798-28-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 99 | H-GLU (OTBU) -OH.H2O | 2419-56-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 101 | H-His (TRT) -oh | 35146-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 104 | H-Lys (boc) -oh | 2418-95-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 105 | H-Lys (alloc) -oh | 6298/3/9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 106 | FMOC-ONN-OH.HCl | 201046-57-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 107 | H-ONN (BOC) -OH | 13650-49-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 109 | H-ser (tbu) -oh | 18822-58-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 110 | H-ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 112 | H-thr (TBU) -oh | 4378-13-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 114 | H-Trp (Boc) -oh | 146645-63-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 118 | H-TYR (TBU) -OH | 18822-59-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 120 | HD-TYR (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 121 | H-tyr (me) -oh.hcl | 67423-44-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 124 | FMOC-Lys (IPR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 125 | H-Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
Apie
Kompensacija
„Gentolex“ teikia puikios kokybės produktus, jei klientas padidina kokią nors produkto kokybę per reikiamą laiko tarpą su pakankamais įrodymais, mes pateiksime būtiną analizę ir vertinimą, kad suaktyvintume kompensacijų procedūras.
Gamyba
Farmacijos produktų pajėgumai pasiekė tonų laipsnį, cheminių produktų pajėgumai pasiekia 100TONS+ klasę, galimybės yra gerai pasirengusios aptarnauti klientus visame pasaulyje.
Tyrimai ir plėtra
Kiekvienais metais R&D komanda sudaro planą kurti įvairius naujus produktus, kai nustatytos tikslai, kiekvienas komandos narys turės tęsti atsakomybę už KPI ir vykdant paskatų politiką.
